Modern therapeutic dietary foods in the complex therapy of chronic reflux gastritis, not associated with HP infection
https://doi.org/10.21518/ms2023-095
Abstract
Introduction. Dietary nutrition is one of the most important and physiological therapeutic and preventive approaches for chronic reflux gastritis (CRG), not associated with HP infection.
Aim. To analyze the effectiveness and safety of the use of specialized therapeutic nutrition (produced by LEOVIT) in chronic reflux gastritis (CRG), not associated with HP infection, in the acute phase.
Materials and methods. A comparative randomized study included 40 patients with CRG, not associated with HP infection, in the acute phase. During the one-month course, standard diet therapy was used in the control group (20 patients), and in the patients of the main group (20 patients), diet therapy was carried out using specialized dietary products. The dynamics of clinical manifestations, changes in esophagogastroduodenoscopy (EGDS), blood test parameters, and the severity of dysbiosis were studied. Statistical processing of the research results was carried out with the determination of the significance of the mean values using the Student’s t-test.
Results. It was found that the studied specialized therapeutic nutrition (oatmeal porridge with herbs and flax seed, vegetable soup with herbs and oatmeal, gastric jelly LEOVIT) have pleasant organoleptic properties, do not cause intolerance and allergic manifestations, restore digestion, improve the state of intestinal microflora, improve the quality of life of patients. According to endoscopic studies in the esophagus of patients in the main group, compared with patients in the comparison group, “normal” mucosa was statistically significantly more common (95 vs. 60% of cases) and catarrhal esophagitis was less common (5 vs. 40% of cases). The number of patients with an admixture of bile in the lumen of the stomach in patients of the main group compared with patients of the control group was found significantly less frequently in 20% of cases versus 75% of cases.
Conclusion. The investigated approach to diet therapy with the use of specialized therapeutic nutrition in CRG is completely safe and recommended by the authors for long-term use in patients with this pathology.
About the Authors
O. N. MinushkinRussian Federation
Oleg N. Minushkin, Dr. Sci. (Med.), Professor, Head of the Department of Gastroenterology
19, Bldg. 1a, Marshal Timoshenko St., Moscow, 121359
I. V. Zverkov
Russian Federation
Igor V. Zverkov, Dr. Sci. (Med.), Professor of the Department of Gastroenterology
19, Bldg. 1a, Marshal Timoshenko St., Moscow, 121359
L. V. Maslovskii
Russian Federation
Leonid V. Maslovskii, Dr. Sci. (Med.), Associate Professor of the Department of Gastroenterology
19, Bldg. 1a, Marshal Timoshenko St., Moscow, 121359
V. S. Inevatova
Russian Federation
Victoria S. Inevatova, Gastroenterologist
37, Gagarin St., Chekhov, Moscow Region, 142304
Yu. G. Kuznetsova
Russian Federation
Yuliya G. Kuznetsova, Cand. Sci. (Med.), Assistant of the Department of Gastroenterology
19, Bldg. 1a, Marshal Timoshenko St., Moscow, 121359
T. L. Pilat
Russian Federation
Tatiana L. Pilat, Dr. Sci. (Med.), Professor, Leading Researcher
31, Budyonnyy Ave., Moscow, 105275
References
1. El-Serag H.B., Sweet S., Winchester C.C., Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014;63(6):871–880. https://doi.org/10.1136/gutjnl-2012-304269.
2. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., Zayratyants O.V. et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. (In Russ.) https://doi.org/10.22416/1382-4376-2020-30-4-70-97.
3. Lagergren J., Bergström R., Lindgren A., Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825–831. https://doi.org/10.1056/NEJM199903183401101.
4. Cook M.B., Corley D.A., Murray L.J., Liao L.M., Kamangar F., Ye W. et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON). PLoS ONE. 2014;9(7):e103508. https://doi.org/10.1371/journal.pone.0103508.
5. Pohl H., Wrobel K., Bojarski C., Voderholzer W., Sonnenberg A., Rösch T., Baumgart D.C. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol. 2013;108(2):200–207. https://doi.org/10.1038/ajg.2012.387.
6. Chang J.T., Katzka D.A. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med. 2004;164(14):1482–1488. https://doi.org/10.1001/archinte.164.14.1482.
7. Pilat T.L., Minushkin O.N., Lazebnik L.B., Zverkov I.V., Kuznetsova Yu.G., Khanferyan R.A. Features of diet therapy for H. pylori associated diseases of the gastrointestinal tract. Meditsinskiy Sovet. 2022;(15):46–61. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-15-46-61.
8. Pilat T.L., Lazebnik L.B., Kuznetzova Yu.G., Khanferyan R.A. Features of diet therapy for Clostridium difficile-associated disease. Experimental and Clinical Gastroenterology. 2022;(9):229–239. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-205-9-229-239.
9. Pilat T.L., Kuzmina L.P., Lazebnik L.B., Khanferyan R.A. Features of dietary therapeutic nutrition in COVID-19 with gastrointestinal tract damage. Therapy. 2022;(7):155–167. (In Russ.) https://doi.org/10.18565/therapy.2022.7.155-167.
10. Pilat T.L., Radysh I.V., Surovtsev V.V., Korosteleva M.M., Khanferyan R.A. Possibilities of specialized dietary correction of gastrointestinal tract disorders in patients with COVID-19 viral infection. Lechaschi Vrach. 2020;(8):11–15. (In Russ.) https://doi.org/10.26295/OS.2020.90.44.001.
11. Pilat T.L., Khanferyan R.A. Specialized dietetic dietary factors as factors in the increasing the pharmacotherapy efficacy of gastrointestinal diseases. Therapy. 2020;(6):212–218. (In Russ.) https://doi.org/10.18565/therapy.2020.6.212-218.
12. Pilat T.L., Kuzmina L.P., Lashina E.L., Kolyaskina M.M., Bezrukavnikova L.M., Bessonov V.V. et al. Experience of application of specialized food product of dietary therapeutic and dietary preventive nutrition in case of inflammatory diseases of gastrointestinal tract. Meditsinskiy Sovet. 2020;(4):107–113. (In Russ.) https://doi.org/10.21518/2079-701X-2020-4-107-113.
13. Pilat T.L., Lashina E.L., Kolyaskina M.M., Bezrukavnikova L.M., Korosteleva M.M., Gurevich K.G. et al. The use of a specialized dietary cocktail with herbal ingredients for reparative processes in various diseases of the gastrointestinal tract. Poliklinika. 2020;(1):100–104. (In Russ.) Available at: https://www.poliklin.ru/imagearticle/202001(2)/100-104.pdf.
14. Ardatskaya M.D., Belmer S.V., Dobritsa V.P., Zakharenko S.M., Lazebnik L.B., Minushkin O.N. et al. Intestinal dysbiosis (dysbiosis): current state of the problem, complex diagnosis and therapeutic correction. Experimental and Clinical Gastroenterology. 2015;(5):13–50. (In Russ.) Available at: https://elibrary.ru/item.asp?id=23702018.
Review
For citations:
Minushkin ON, Zverkov IV, Maslovskii LV, Inevatova VS, Kuznetsova YG, Pilat TL. Modern therapeutic dietary foods in the complex therapy of chronic reflux gastritis, not associated with HP infection. Meditsinskiy sovet = Medical Council. 2023;(6):126-133. (In Russ.) https://doi.org/10.21518/ms2023-095